Oncternal Therapeutics (NASDAQ:ONCT) Downgraded to “Hold” at Northland Capmk

Northland Capmk lowered shares of Oncternal Therapeutics (NASDAQ:ONCT) from a strong-buy rating to a hold rating in a report issued on Thursday, Zacks.com reports.

Several other analysts have also recently issued reports on ONCT. Brookline Capital Management restated a hold rating on shares of Oncternal Therapeutics in a research note on Thursday. HC Wainwright dropped their price target on Oncternal Therapeutics from $19.00 to $18.00 and set a buy rating on the stock in a research report on Monday, August 12th. Northland Securities reaffirmed a market perform rating and issued a $2.00 price target on shares of Oncternal Therapeutics in a report on Thursday. Finally, StockNews.com began coverage on shares of Oncternal Therapeutics in a research note on Sunday, September 8th. They set a hold rating on the stock. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of Hold and a consensus price target of $20.00.

Oncternal Therapeutics Stock Down 14.1 %

ONCT stock opened at $1.46 on Thursday. The stock’s 50 day moving average is $5.37 and its two-hundred day moving average is $7.48. Oncternal Therapeutics has a 52-week low of $1.32 and a 52-week high of $13.14. The company has a market capitalization of $4.32 million, a PE ratio of -0.12 and a beta of 1.39.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.03) by $0.14. The firm had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $0.24 million. Oncternal Therapeutics had a negative net margin of 1,948.70% and a negative return on equity of 136.10%. During the same period in the prior year, the company posted ($3.00) earnings per share. As a group, sell-side analysts anticipate that Oncternal Therapeutics will post -11.4 EPS for the current year.

Institutional Trading of Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC bought a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned approximately 0.84% of Oncternal Therapeutics at the end of the most recent reporting period. 16.05% of the stock is currently owned by institutional investors and hedge funds.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.